Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | PBM |
|---|---|---|
| Share price | $0.455 | $5.00 |
| Market cap | $1.00M | — |
| 1-day change | -13.12% | -2.34% |
| YTD return | — | -82.59% |
| 1-year return | — | -97.05% |
| P/E ratio (TTM) | 0.01 | — |
| EPS (TTM) | $63.74 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $150.78 |
| 52-week low | $0.4535 | $1.92 |
| Distance from 52-week high | -99.13% | -96.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +1858.24% | — |
| Average volume | 3.72M | 94.85K |
| Shares outstanding | 2.20M | — |
| Employees | 11 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BDRX vs PBM FAQ
Are Biodexa Pharmaceuticals American Depositary Shs and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.